Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

MPN Congress 2022 | A paradigm shift in the diagnosis and treatment of MPNs

Hans Hasselbalch • 24 Nov 2022
MPN Congress 2022
Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Interferon

Hans Hasselbalch, MD, PhD, Zealand University Hospital Roskilde, Roskilde, University of Copenhagen, Copenhagen, Denmark, gives a presentation on advances in the diagnosis and treatment of myeloproliferative neoplasms (MPNs) at the 14th International Congress on Myeloproliferative Neoplasms held in New York City, NY.

Related Videos

Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US 2:03
Hematocrit control among patients with high- or low-risk PV receiving SoC treatment in the US
Aaron Gerds • 5 Dec 2025
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM 4:27
Results of a Phase II trial of pirtobrutinib plus venetoclax in previously treated WM
Jorge Castillo • 8 Dec 2025
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM 2:54
Final report of a Phase II study of venetoclax and ibrutinib in previously untreated WM
Jorge Castillo • 8 Dec 2025
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat 2:12
Correlation between IL-8 and TNF-alpha levels and OS in patients with R/R MF treated with imetelstat
Prithviraj Bose • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals